Prelude Therapeutics Incorporated (PRLD) has been on a downward spiral lately with significant selling pressure. After ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

HC Wainwright reiterated their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research note released on Friday,Benzinga reports. They currently have a $5.00 target ...

Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorpora PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session ...

Analyst Peter Lawson of Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), reducing the price target to $1.00. Peter Lawson has given his Sell rating due to a ...

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from ...

Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the shares. The updated SMARCA2 degrader data show ...

Prelude Therapeutics Inc (PRLD)股票已触及新的52周低点，交易价格为1.1美元，该公司正面临充满挑战的市场环境。这一最新价格标志着这家生物制药公司的重大下跌，过去一年其股票价值下降了65%。投资者正密切关注PRLD的表现，因为该公司正在经历一段波动期，并寻求在竞争激烈的生物科技板块重新站稳脚跟。52周低点成为该公司短期前景和潜在战略调整的关键指标。

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the third quarter ended ...

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from ...